Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05055648
Other study ID # DCPT101008134
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 1, 2022
Est. completion date May 1, 2030

Study information

Verified date October 2022
Source University of Aarhus
Contact Dorte Winter
Phone +45 78456442
Email dorte.skriver.winther@auh.rm.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).


Description:

PROTECT is a unblinded international multicenter randomized phase III study for patients with operable EC or EGC receiving nCXT (standard of care) or nCPT (intervention). The study will be open-label for the patient and the treating physician. The radiation dose is either 41.4 Gy in 23 fractions, five fractions per week or 50.4 Gy in 28 fractions, five fractions per week. Prior to trial opening, each proton center will determine a single dose regimen for all patients treated in that specific proton center and its assigned photon centers. The protocol prescribes that all referring centers will use the same chemotherapy regimen, which is weekly carboplatin (AUC 2), and paclitaxel (50 mg/m2), five cycles, irrespective of choice of dose regimen. Chemotherapy is a non-investigational drug. Prior to referral to any proton therapy center, patients will be randomed (1:1) to either nCXT or nCPT. Only patients randomized to the PT arm will be referred to a PT center. Randomization will be performed centrally using an online 24-hour web-based system maintained by the Clinical Trial Office at Aarhus University Hospital, ensuring allocation concealment to the clinical investigators. The method of randomization will be stratified permuted blocks of size 4 and 6 (selected randomly) with the following strata: - Histopathology (non-squamous vs squamous cell carcinoma) - Planned surgical technique (open versus minimal invasive/robotic or hybrid) - Proton center and sites assigned to this center (which will deliver the nCXT)


Recruitment information / eligibility

Status Recruiting
Enrollment 396
Est. completion date May 1, 2030
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with histologically verified squamous cell carcinoma or adenocarcinoma (including signet cell carcinoma and large cell carcinoma, not further specified) of the esophagus (E) or gastro-esophageal junction (GEJ). - FDG PET/CT performed. - Tumor stage according to TNM (8th edition): cT1-4a and/or cN+, cM0. - Age =18 years. - Performance status WHO =2. - Adequate laboratory findings: hematological: hemoglobin > 90 g/L, absolute neutrophil count (ANC) = 1,5 x 109/L, platelets = 75 x 109/L hepatic: bilirubin = 1.5 x upper limit of normal (ULN), ALAT = 3 x ULN renal: creatinine = 1.5 x ULN, GFR (may be calculated) > 30 ml/min - MDT decision on suitability to undergo curatively intended nCXT or nCPT followed by surgery. - Planned transthoracic esophagectomy or gastrectomy being open, minimally invasive of combination of both. - Ability to adhere to procedures for study and follow-up. - Patients with low risk cancers with a life expectancy above 5 years (e.g. low risk prostate cancer) are allowed in the study. Adequately treated diagnoses such as cervix uteri carcinoma in situ, in situ urothelial carcinoma or localized non-melanoma skin cancer are allowed, regardless of time of diagnosis. - Patients of childbearing potential: pregnancy prevention according to the standards of each country. Patients of childbearing potential must present a negative pregnancy test. Patients and their partners must use effective contraception. Patients of childbearing potential included in the study must use oral contraceptives, intrauterine devices, depot injection of progestin subdermal implantation, a hormonal vaginal ring, or transdermal patch during the study treatment and one month after. Exclusion Criteria: Patients who meet one or more of the following exclusion criteria cannot be included in the study: - Prior thoracic XT or PT, chemotherapy or surgical resection in the esophageal/gastric region (previous EMR or ESD is allowed). - Tumor < 3 cm from oropharyngeal sphincter. - Planned transhiatal resection - Patients with other previous malignancies are excluded unless a complete remission or complete resection was achieved at least 5 years prior to study entry. - Any unstable systemic disease (including clinically significant lung and cardiovascular disease, unstable angina, New York Heart Association (NYHA) grade III-IV congestive heart, severe hepatic, renal or metabolic disease or active inflammatory bowel disease). - Symptomatic peripheral neuropathy greater than grade 1 (scored according to CTCAE v5.0). - Any other serious or uncontrolled illness, which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial. - Unable to understand and digest study patient information or comply with study treatment and safety instructions. - Gastro-esophageal stent within the irradiated volume.

Study Design


Intervention

Radiation:
Photon Radiotherapy
nCXT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions
Proton Radiotherapy
nCPT consists of weekly carboplatin and paclitaxel for 5 weeks, following the CROSS trial. The radiation dose will be either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions

Locations

Country Name City State
Belgium Catholic University of Leuven Leuven
Denmark Aarhus University Hospital (AUH) Aarhus
France Centre Léon Bérard (CLB) Lyon
France Centre Antoine Lacassagne (CAL) Nice
France Institut Curie Paris
Germany Technische Universität Dresden (TUD) Dresden
Italy Centro Nazionale di Adroterapia Oncologica (CNAO) Pavia
Italy Azienda Provinciale Per I Servizi Sanitari (APSS) Trento
Netherlands Academisch Ziekenhuis Groningen (UMCG) Groningen
Netherlands Stichting Maastricht Radiation Oncology (MAASTRO) Maastricht
Switzerland Paul Scherrer Institute (PSI) Villigen
United Kingdom University College London Hospital (UCLH) London
United Kingdom The Christie NHS foundation trust Manchester

Sponsors (19)

Lead Sponsor Collaborator
University of Aarhus Aarhus University Hospital, Academisch Ziekenhuis Groningen, Agenzia Nazionale per i Servizi Sanitari Regionali, Centre Antoine Lacassagne, Centre Leon Berard, CNAO National Center of Oncological Hadrontherapy, HollandPTC, IBA worldwide, Institut Curie, KU Leuven, Maastro Clinic, The Netherlands, Paul Scherrer Institut, Center for Proton Therapy, Technische Universität Dresden, The Christie NHS Foundation Trust, University College London Hospitals, University College, London, University of Leeds, Varian- A Siemens Healthineer Company

Countries where clinical trial is conducted

Belgium,  Denmark,  France,  Germany,  Italy,  Netherlands,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Total toxicity burden (TTB) The combined toxicity scale TTB used in the trial by Lin et al (Lin 2020) from randomization until 90 days after surgery
Other Concordance of observed pulmonary complications with predicted complications from NTCP models Comparison of observed and predicted toxicity rates up to 5 years
Other Blood biomarkers as predictors for treatment failure circulating tumor DNA up to 5 years
Other Proportion of patients receiving adjuvant immunotherapy The actual number of patients starting adjuvant immunotherapy will be recorded up to 5 years
Other Cost-effectiveness of proton therapy relative to photon therapy Incremental cost effectiveness ratios (ICERs), cost per QALY gained, cost per complication avoided, and cost per total toxicity burden avoided will be reported. up to 5 years
Other FDG/PET CT as predictors for treatment failure Correlation between diagnostic PET, planning PET-CT and PET at 12 months 12 months
Other Concordance of observed cardiac complications with predicted Comparison of observed and predicted toxicity rates Up to 5 years
Primary Pulmonary complications Incidence of pulmonary complications during and following nCPT or nCXT and surgery from randomization until 90 days after surgery
Secondary Early toxicity Predefined items = grade 2 scored by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 from start of nCPT or nCXT until surgery
Secondary Late toxicity Predefined items = grade 2 scored by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 up to 5 years
Secondary Postoperative complications Predefined items scored by Clavien-Dindo and Comprehensive Complications Index (CCI) from surgery until 90 days after surgery
Secondary Major cardiovascular events (MACE) Predefined cardiovascular events scored by MACE up to 5 years
Secondary Patient-reported outcome measures EORTC quality of life questionnaire up to 5 years
Secondary Compliance with trimodality treatment The proportion of patients complying with trimodality treatment in each arm 3 months
Secondary Pathological response tumor regression grade for the primary tumor scored according to Mandard score. immediately after surgery
Secondary Cumulative incidence of loco-regional failure Locoregional failure evaluated according to RECIST with all failures within the irradiated volume counting as events. from date of randomization up to 5 years
Secondary Pattern of failure First site of failure will be divided in loco-regional lymph node failures, loco-regional failures in anastomosis, and distant extra-cranial and intra-cranial failures. All loco-regional failures will be divided in failures inside and outside the treatment volume, which is defined to be within the specified treatment dose. up to 5 years
Secondary Disease-free survival (DFS) Disease control evaluated according to RECIST with any recurrence (locoregional or distant) as well as death from any cause, whatever occurs first, will be considered as events. up to 5 years
Secondary Overall survival (OS) Death from all causes will considered as events up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
Not yet recruiting NCT05542680 - Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer N/A
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT00003864 - Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus Phase 2
Recruiting NCT05491616 - Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Completed NCT00400114 - Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04615806 - The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy N/A
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Active, not recruiting NCT03962179 - Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent) N/A
Terminated NCT01446874 - Prevention of Post-operative Pneumonia (POPP) Phase 2/Phase 3
Completed NCT03468634 - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy N/A
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Recruiting NCT02544737 - Apatinib for Metastatic Esophageal Cancer. Phase 2